Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.

Updated, longer-term results from the COMMANDS trial show a promising trend toward improved overall survival with ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Japan: Researchers have found in a recent multicenter, open-label, single-arm study that Ferric citrate hydrate (FCH) ...

Adding niraparib to abiraterone acetate and prednisone may help slow cancer growth for patients with metastatic ...

Dr. Simrit Parmar, an associate professor in the College of Medicine at Texas A&M University and founder of the ...

In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of ...

A Falmouth teen, Jayden Wilsey, is the first to receive gene therapy to treat sickle cell at Boston Children's Hospital.

Rusfertide could be a new treatment option for patients with polycythemia vera, according to Andrew Kuykendall, MD.